|
|
||||||||
and PKC
From 1 Schepens Eye Research Institute and the Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; and 2 Institut Pasteur de Lille, Centre National de la Recherche Scientifique, Lille, France.
| Abstract |
|---|
|
|
|---|
METHODS. Lacrimal gland acini were prepared by collagenase digestion, and changes in intracellular Ca2+ ([Ca2+]i) were measured using fura-2 as a fluorescent probe.
RESULTS. Preactivation of PKC by phorbol 12-myristate 13-acetate (PMA), or
inhibition of protein phosphatase type 1/2A (PP1/2A) by calyculin A,
decreased both the [Ca2+]i transient and the
plateau of [Ca2+]i induced by increasing
concentrations of carbachol, a cholinergic agonist. Staurosporine, an
inhibitor of PKC, completely reversed the effect of PMA. Inhibition of
the Ca2+-independent PKC isoforms PKC
and -
, but not
the Ca2+-dependent isoform PKC
substantially reversed
the inhibitory effect of PMA on cholinergic agonist-induced
Ca2+ elevation. The inhibitory effect of PMA was obtained
only in the presence of extracellular Ca2+, suggesting that
PKC inhibits the influx of Ca2+. PMA completely inhibited
the cholinergic agonist-induced plateau of
[Ca2+]i. PMA and calyculin A decreased both
the [Ca2+]i transient and the plateau of
[Ca2+]i induced by thapsigargin, further
supporting the idea that PKC modulates the entry of Ca2+.
CONCLUSIONS. In the lacrimal gland, agonist-induced changes in [Ca2+]i are negatively regulated by PKC-dependent phosphorylation of a target protein(s) that is sensitive to PP1/2A.
| Introduction |
|---|
|
|
|---|
It is well documented that cholinergic agonists stimulate the release of intracellular Ca2+ and influx of Ca2+ from the extracellular medium in the lacrimal gland.7 8 9 10 The Ca2+ response usually consists of an initial large Ca2+ transient (peak) due to IP3-induced Ca2+ release from intracellular stores followed by a sustained plateau of [Ca2+]i due to influx of Ca2+. There is considerable evidence that depletion of IP3-sensitive intracellular Ca2+ stores leads to activation of this secondary Ca2+ entry, a process termed by Putney11 as capacitative Ca2+ entry.11 12
Thapsigargin, a specific inhibitor of endomembrane Ca2+-ATPase activity, inhibits sequestration of Ca2+ that has leaked from the intracellular stores, thereby decreasing [Ca2+] within the stores.13 It is this decrease in [Ca2+] within the stores that is believed to signal entry of Ca2+ into the cells by stimulating capacitative entry of Ca2+.11 Thus, thapsigargin increases [Ca2+]i without production of IP3 and can be used to study entry of Ca2+ into cells.
Recent reports have shown that preactivation of PKC results in negative feedback on cholinergic-induced Ca2+ release in the lacrimal gland, implicating PKC in the mechanism of desensitization of the cholinergic response.14 15 16 Although it has been shown that preactivation of PKC results in a decreased production of IP3, the effect of PKC on Ca2+ influx in the lacrimal gland has not been investigated.
PKC is a family of closely related serine and threonine kinases
consisting of at least 11 isoforms divided into three
groups17
: calcium- and phospholipid-dependent protein
kinases PKC
, -ßI, -ßII, and -
; calcium-independent and
phospholipid-dependent protein kinases PKC
, -
, -
, -
, and
-µ; and calcium- and phospholipid-independent protein kinases
PKC
/
and -
. All PKC isoforms except PKCµ have a
pseudosubstrate sequence in their N-terminal part that is thought to
interact with the catalytic domain to keep the enzyme inactive in
resting cells.18
19
In a recent study, we synthesized and
N-myristoylated three peptides derived from the
pseudosubstrate sequences of PKC
, -
, and -
, three PKC isoforms
present in lacrimal gland acini.20
Using these peptides,
we showed that PKC
, -
, and -
isoforms are differentially
involved in agonist-induced protein secretion.21
| Materials and Methods |
|---|
|
|
|---|
Preparation of Lacrimal Gland Acini
All experiments conformed to the guidelines established by the
ARVO Statement for the Use of Animals in Ophthalmic and Vision Research
and were approved by the Schepens Eye Research Institute Animal Care
and Use Committee. Both exorbital lacrimal glands were removed from
male Wistar rats (125200 g body weight) that had been anesthetized
with CO2 for 1 minute and then decapitated.
Dispersed acini were isolated by collagenase digestion, as described
previously.22
Lacrimal glands were trimmed of fatty and
connective tissue and fragmented into small pieces 2 to 3 mm in
diameter. The pieces were then washed at 37°C in KrebsRinger
bicarbonate (KRB) buffer (containing, in mM, 119 NaCl, 4.8 KCl, 1
CaCl2, 1.2 MgSO4, 1.2
KH2PO4, and 25
NaHCO3), supplemented with 10 mM Hepes, 5.5 mM
glucose, and 0.5% bovine serum albumin (BSA; KRB-Hepes; pH 7.4).
Lacrimal gland acini were prepared by incubating tissue pieces with
collagenase (CLS III, 150 U/ml) in 10 ml KRB-Hepes buffer for 30
minutes at 37°C under a stream of 95% O2-5%
CO2. Lacrimal lobules were subjected to gentle
pipetting 10 times at regular time intervals through tips of decreasing
diameter. The preparation was then filtered through nylon mesh
(150-µm pore size) and the acini pelleted by centrifugation
(50g, 2 minutes). The pellet was washed twice by
centrifugation (50g, 2 minutes) through a 4% BSA solution
made in KRB-Hepes buffer. The dispersed acini were allowed to recover
for 30 minutes in 5 ml fresh KRB-Hepes buffer containing 0.5% BSA.
Measurement of [Ca2+]i
Acini were incubated in KRB-Hepes buffer containing 0.5%
BSA, 0.5 µM fura-2 tetra-acetoxymethyl ester, 10% Pluronic F127, and
250 µM sulfinpyrazone for 60 minutes at 22°C. For the experiments
involving the myristoylated PKC pseudosubstrate-derived peptides, acini
were incubated first at 37°C for 30 minutes with the peptides and
then transferred to 22°C, and fura-2 was added as has been described.
For the experiments involving pretreatment with PMA or calyculin A,
acini were loaded with fura-2, and then PMA (500 nM) or calyculin A
(100 nM) was added 10 minutes before the end of the incubation period.
Where indicated, staurosporine (1 µM) was added 10 minutes before
addition of PMA. The cells were then washed with KRB-Hepes buffer
containing 250 µM sulfinpyrazone, and fluorescence was measured at
22°C. Fluorescence was measured at excitation wavelengths of 340 and
380 nm and an emission wavelength of 505 nm, as previously
described.23
To calculate [Ca2+],
5.6 mM EGTA, 7.5 mM Tris-HCl (pH 7.5), and 1% Triton X-100 were added
at the end of the reaction to obtain minimum fluorescence. Maximum
fluorescence was determined by the addition of 14.5 mM
CaCl2. The dissociation constant of 135 nM for
fura-2 at 22°C was used to calculate [Ca2+]
by the ratio method.23
PKC Pseudosubstrate-Derived Peptide Synthesis
Myristoylated PKC pseudosubstrate-derived peptides were
synthesized by butyloxycarbonyl strategy on resin (MHBA; Novabiochem,
Meudon, France) using an automated synthesizer (model 430A; Applied
Biosystems; Foster City, CA). Protocols and reagents were used as
recommended by the manufacturer. Myristic acid was coupled to the
peptide using dicyclohexylcarbodiimide hydroxybenzotriazole. Peptides
were purified by reversed-phase high-performance liquid chromatography
(HPLC) on a preparative column (30 x 0.9 cm,
C4; Vydac, Hesperia, CA) using a trifluoroacetic
acid-acetonitrile solvent system. Peptide integrity was monitored by
amino acid analysis and mass spectrometry.
Data Presentation and Statistical Analysis
Where appropriate, data are expressed as means ± SEM. The
data were statistically analyzed using Students t-test for
paired values. P < 0.05 was considered to be
significant.
| Results |
|---|
|
|
|---|
and -
,
but not the Ca2+-dependent isoform PKC
, by
synthetic peptides derived from the pseudosubstrate sequence of each
isoform, substantially reversed the inhibitory effect of PMA on
cholinergic-induced Ca2+ elevation. The effect of
PMA was obtained only in the presence of extracellular
Ca2+, suggesting that PKC inhibits the influx of
Ca2+. PMA and calyculin A decreased both the
[Ca2+]i transient and the
plateau of [Ca2+]i
induced by thapsigargin, further supporting the idea that PKC modulates
entry of Ca2+. We concluded that in the lacrimal
gland, agonist-induced changes in
[Ca2+]i are negatively
regulated by phosphorylation by PKC.
Effect of Preactivation of PKC on Carbachol-Induced Changes in
[Ca2+]i
It is well documented that cholinergic agonists increase
[Ca2+]i in the lacrimal
gland. The response consists of an initial large
Ca2+ transient (peak) due to
Ca2+ release from intracellular stores, followed
by a sustained plateau of
[Ca2+]i due to influx of
Ca2+.24
25 Figure 1A
shows a typical trace depicting the effect of increasing
concentrations of carbachol on Ca2+ release from
fura-2loaded lacrimal gland acinar cells. The release of
Ca2+ is dependent on the concentration of
carbachol, with a maximum release reached at
10-4 M carbachol. Figure 1
shows the effect of
increasing concentrations of carbachol on the
Ca2+ transient (peak, Fig. 1B ) and the plateau of
[Ca2+]i (Fig. 1C)
. Peak
and plateau values of Ca2+ show a similar dose
dependency with a median effective concentration
(EC50) of approximately 5 µM carbachol.
Preincubation of acini with PMA (500 nM) to activate PKC resulted in a
dramatic inhibition of carbachol-induced Ca2+
release (Fig. 1A)
. PMA pretreatment resulted in a significant
inhibition of both the
[Ca2+]i transient induced
by carbachol concentrations of 10-6,
10-5, and 10-4 M (Fig. 1B)
, as well as an inhibition of the plateau of
[Ca2+]i, but only at
carbachol concentrations of 10-6 and
10-5 (Fig. 1C)
. These results confirm previous
reports and show that both the release of Ca2+
from intracellular stores and the influx of Ca2+
are negatively modulated by PKC.
|
|
and
myr-PKC
, but not myr-PKC
, reversed the effect of PMA on
[Ca2+]i transient. The
effect of PMA on the plateau of
[Ca2+]i was reversed only
by myr-PKC
. These results suggest that it is PKC
and -
, but
not -
, that exert the negative feedback on cholinergic-induced
[Ca2+]i elevation in the
lacrimal gland.
Role of Extracellular Ca2+ in the Effect of PMA on
Carbachol-Induced Changes in [Ca2+]i
Bird et al.27
showed that although preactivation of
PKC may decrease the IP3 content in the lacrimal
gland, this treatment had no effect on Ca2+
release induced by microinjected IP3. Thus, PKC
does not affect the IP3 receptor. This suggested
to us that PKC may affect the Ca2+ response by
modulating its entry across the plasma membrane, especially because the
plateau [Ca2+]i was
affected by PMA to the same extent as the peak
[Ca2+]i. To test this
hypothesis, we studied the effect of extracellular
Ca2+
([Ca2+]o)
omission (by omitting [Ca2+]o and adding
EGTA, a Ca2+ chelator) on carbachol-induced changes in
[Ca2+]i in untreated and PMA-pretreated
lacrimal gland acini. Omission of [Ca2+]o
plus addition of 2 mM, but not 1 mM, EGTA resulted in an effective
decrease of carbachol-induced [Ca2+]i release
(data not shown). Thus, we used 2 mM EGTA to chelate
[Ca2+]o and studied the effect of PMA
pretreatment on carbachol-induced [Ca2+]i
release. As shown in Figure 3A
(solid line), omission of [Ca2+]o severely
impaired the release of Ca2+ induced by carbachol under all
concentrations tested (compare with Fig. 1A
). Both the peak and plateau
values of Ca2+ were similarly affected by this treatment
(compare Figs. 3B
and 3C
with Figs. 1B
and 1C
). In the absence of
[Ca2+]o, preactivation of PKC by PMA no
longer had an effect on carbachol-induced
[Ca2+]i release (Fig. 3)
. This is in contrast
to the carbachol-induced [Ca2+]i release in
the presence of [Ca2+]o, which was
dramatically inhibited by PMA.
|
|
|
|
| Discussion |
|---|
|
|
|---|
One possible mechanism by which the activation of PKC or the inhibition of PP1/2A may inhibit agonist-induced changes in [Ca2+]i would be the stimulation of Ca2+ uptake by the stores by modifying the activity of the Ca2+-ATPase present in the endomembranes, thereby decreasing the [Ca2+]i. Increased loading of intracellular Ca2+ stores would lead to an inhibition of Ca2+ influx. Indeed, it has been shown that PKC stimulates Ca2+ uptake into the Ca2+ stores of platelets by increasing the activity of the Ca2+-ATPase pump.29 30 The mechanism by which PKC modulates the activity of this pump is not known, but it has been suggested to occur through a mechanism similar to the one used by the cyclic adenosine monophosphate (cAMP)dependent protein kinase A (PKA). In platelets, PKA is thought to increase the activity of the Ca2+-ATPase pump through phosphorylation of an accessory protein, which has been identified as rap1, a low-molecular-weight guanosine triphosphate (GTP)binding protein of the ras superfamily of proteins.31 This is of interest because Bird and Putney32 showed that in the lacrimal gland, [Ca2+]i mobilization may be controlled through a GTP-binding protein, probably one of the low-molecular-weight family. PKC or PP1/2A may also increase the activity of Ca2+-ATPase in the plasma membrane to stimulate efflux of Ca2+. Alternatively, PKC may prevent capacitative entry of Ca2+ by inhibition of IP3 production through a negative feedback on phospholipase C activity. A reduced amount of IP3 would result in a reduced increase in [Ca2+]i and therefore a decreased state of emptiness of the intracellular stores, which would result in decreased influx of Ca2+ from the extracellular milieu. It is well accepted that the filling state of the intracellular Ca2+ stores regulates entry of Ca2+ across the plasma membrane through the capacitative model first proposed by Putney.11 The same mechanism could apply in the case of thapsigargin. A recent study showed that the thapsigargin-induced increase in [Ca2+]i in lacrimal gland acini is not simply through a passive leak of Ca2+ from the intracellular stores, but also depends on a basal level of IP3, and this effect can be blocked by heparin, an IP3 antagonist.33
It is worth noting that neither the activation of PKC nor the inhibition of PP1/2A completely inhibited [Ca2+]i mobilization induced by carbachol or thapsigargin. This implies that [Ca2+]i mobilization is under a complex control that is especially crucial in the case of an exocrine gland such as the lacrimal gland where Ca2+ is necessary to trigger exocytosis.
Using staurosporine, we showed that the inhibitory action of PMA on the
cholinergic-induced increase in
[Ca2+]i is mediated by
PKC because staurosporine completely reversed the effect of PMA.
Staurosporine alone had no effect on carbachol-induced
[Ca2+]i changes, which is
in agreement with the findings of Bird et al.27
In another
set of experiments, we used myristoylated PKC pseudosubstrate-derived
peptides to determine which PKC isoform was implicated in the negative
feedback on cholinergic-induced increase in
[Ca2+]i. We found that
inhibition of PKC
and -
, but not -
, partially reversed the
effect of PMA. It is worth noting that it is the two
Ca2+-independent isoforms, PKC
and -
that
seem to be involved. That a complete reversal of the PMA effect could
not be obtained with the myristoylated PKC peptides may be because of
the temperature used. Indeed, in secretion experiments in which these
peptides were first tested,21
we used a temperature of
37°C and a preincubation period of 60 minutes. In the
Ca2+ experiments, we used a shorter preincubation
period (30 minutes) at 37°C, and the cells were then transferred to a
lower temperature (22°C) for fura-2 loading. It is possible that the
entry of the peptides into the cells or the efficiency of interaction
of these peptides with PKC is temperature sensitive. Nevertheless, our
data suggest that PKC
and -
, but not -
, exert a negative
feedback on cholinergic-induced
[Ca2+]i elevation in the
lacrimal gland.
In summary, we conclude that activation of PKC or inhibition of PP1/2A
results in a negative feedback on cholinergic- and thapsigargin-induced
[Ca2+]i changes. We
suggest that the site of action of PKC-PP1/2A may include the plasma
membrane Ca2+ channels in the inhibition of entry
of Ca2+ and that PKC
and -
, but not -
,
are implicated in the negative feedback on cholinergic-induced
[Ca2+]i elevation in the
lacrimal gland.
| Footnotes |
|---|
Submitted for publication May 14, 1999; revised August 9, 1999; accepted September 17, 1999.
Commercial relationships policy: N.
Corresponding author: Driss Zoukhri, Schepens Eye Research Institute, 20 Staniford Street, Boston, MA 02114. zoukhri{at}vision.eri.harvard.edu
| References |
|---|
|
|
|---|
1-Adrenergic and cholinergic agonists use separate signal transduction pathways in lacrimal gland Am J Physiol 262,G1087-G1096This article has been cited by other articles:
![]() |
E. Evans, W. Zhang, G. Jerdeva, C.-Y. Chen, X. Chen, S. F. Hamm-Alvarez, and C. T. Okamoto Direct interaction between Rab3D and the polymeric immunoglobulin receptor and trafficking through regulated secretory vesicles in lacrimal gland acinar cells Am J Physiol Cell Physiol, March 1, 2008; 294(3): C662 - C674. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Hodges, I. Raddassi, D. Zoukhri, A. Toker, A. Kazlauskas, and D. A. Dartt Effect of Overexpression of Constitutively Active PKC{alpha} on Rat Lacrimal Gland Protein Secretion Invest. Ophthalmol. Vis. Sci., November 1, 2004; 45(11): 3974 - 3981. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |